Therapeutic potential of LIF in multiple sclerosis

Trends in Molecular Medicine

Volumn 16, Issue 11, 2010, Pages 493-500

  Slaets, Helena ^a   Hendriks, Jerome J A ^a   Stinissen, Piet ^a   Kilpatrick, Trevor J ^b   Hellings, Niels ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIA INHIBITORY FACTOR;

ARTICLE; DEMYELINATION; DRUG ACTIVITY; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN;

ANIMALS; CELL PROLIFERATION; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; HUMANS; LEUKEMIA INHIBITORY FACTOR; MULTIPLE SCLEROSIS; NEURONS; STEM CELLS;

EID: 78049299952     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.08.007     Document Type: Article

References (82)

1. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
2. Vanderlocht J., et al. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J. Neurosci. Res. 2006, 83:763-774.
3. Heinrich P.C., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
4. Soilu-Hanninen M., et al. Expression of LIF and LIF receptor beta in Alzheimer's and Parkinson's diseases. Acta Neurol. Scand. 2010, 121:44-50.
5. Banner L.R., et al. Leukemia inhibitory factor is expressed in astrocytes following cortical brain injury. Exp. Neurol. 1997, 147:1-9.
6. Dowsing B.J., et al. Expression of leukemia inhibitory factor in human nerve following injury. J. Neurotrauma 2001, 18:1279-1287.
7. Kurek J.B., et al. Leukaemia inhibitory factor (LIF) production in a mouse model of spinal trauma. Neurosci. Lett. 1998, 249:1-4.
8. Lehtimaki K.A., et al. Expression of cytokines and cytokine receptors in the rat brain after kainic acid-induced seizures. Brain Res. Mol. Brain Res. 2003, 110:253-260.
9. Suzuki S., et al. Immunohistochemical detection of leukemia inhibitory factor after focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 2000, 20:661-668.
10. Cheema S.S., et al. Leukemia inhibitory factor prevents the death of axotomised sensory neurons in the dorsal root ganglia of the neonatal rat. J. Neurosci. Res. 1994, 37:213-218.
11. Tham S., et al. Leukemia inhibitory factor enhances the regeneration of transected rat sciatic nerve and the function of reinnervated muscle. J. Neurosci. Res. 1997, 47:208-215.
12. Suzuki S., et al. Activation of cytokine signaling through leukemia inhibitory factor receptor (LIFR)/gp130 attenuates ischemic brain injury in rats. J. Cereb. Blood Flow Metab. 2005, 25:685-693.
13. Ueki Y., et al. STAT3 activation in photoreceptors by leukemia inhibitory factor is associated with protection from light damage. J. Neurochem. 2008, 105:784-796.
14. Joly S., et al. Leukemia inhibitory factor extends the lifespan of injured photoreceptors in vivo. J. Neurosci. 2008, 28:13765-13774.
15. Leibinger M., et al. Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J. Neurosci. 2009, 29:14334-14341.
16. Buntinx M., et al. Immune-mediated oligodendrocyte injury in multiple sclerosis: molecular mechanisms and therapeutic interventions. Crit. Rev. Immunol. 2002, 22:391-424.
17. Azari M.F., et al. Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury. J. Neuropathol. Exp. Neurol. 2006, 65:914-929.
18. Kerr B.J., Patterson P.H. Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 2005, 51:73-79.
19. Emery B., et al. Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor. Neuroscience 2006, 137:463-472.
20. Slaets H., et al. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 2008, 8:1237-1247.
21. Adachi T., et al. Influence of LIF and BMP-2 on differentiation and development of glial cells in primary cultures of embryonic rat cerebral hemisphere. J. Neurosci. Res. 2005, 79:608-615.
22. Franklin R.J., Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 2008, 9:839-855.
23. Stankoff B., et al. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J. Neurosci. 2002, 22:9221-9227.
24. Ishibashi T., et al. Astrocytes promote myelination in response to electrical impulses. Neuron 2006, 49:823-832.
25. Ishibashi T., et al. Leukemia inhibitory factor regulates the timing of oligodendrocyte development and myelination in the postnatal optic nerve. J. Neurosci. Res. 2009, 87:3343-3355.
26. Emery B., et al. Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7859-7864.
27. Butzkueven H., et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. 2002, 8:613-619.
28. Butzkueven H., et al. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia 2006, 53:696-703.
29. Marriott M.P., et al. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia 2008, 56:686-698.
30. Bell M.C., Carroll G.J. Rheumatoid synovial fluid contains bioactive leukemia inhibitory factor with cartilage degrading activity - another target for chondroprotective intervention. J. Rheumatol. 2000, 27:332-338.
31. McKenzie R.C., et al. A novel endogenous mediator of cutaneous inflammation: leukemia inhibitory factor. Acta Derm. Venereol. 1996, 76:111-114.
32. Kerr B.J., Patterson P.H. Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse. Exp. Neurol. 2004, 188:391-407.
33. Damas P., et al. Sepsis and serum cytokine concentrations. Crit. Care Med. 1997, 25:405-412.
34. Szepietowski J., et al. Elevated leukaemia inhibitory factor (LIF) expression in lesional psoriatic skin: correlation with interleukin (IL)-8 expression. J. Dermatol. 2001, 28:115-122.
35. Waring P.M., et al. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1993, 36:911-915.
36. Weber M.A., et al. Endogenous leukemia inhibitory factor attenuates endotoxin response. Lab. Invest. 2005, 85:276-284.
37. Waring P.M., et al. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1337-1341.
38. Zhu M., et al. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J. Immunol. 2001, 166:2049-2054.
39. Escary J.L., et al. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 1993, 363:361-364.
40. Shen M.M., et al. Expression of LIF in transgenic mice results in altered thymic epithelium and apparent interconversion of thymic and lymph node morphologies. EMBO J. 1994, 13:1375-1385.
41. Metcalfe S.M., et al. Leukemia inhibitory factor is linked to regulatory transplantation tolerance. Transplantation 2005, 79:726-730.
42. Hendriks J.J., et al. Leukemia inhibitory factor modulates production of inflammatory mediators and myelin phagocytosis by macrophages. J. Neuroimmunol. 2008, 204:52-57.
43. Sugiura S., et al. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur. J. Neurosci. 2000, 12:457-466.
44. Hilton D.J., et al. Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J. Cell Physiol. 1991, 146:207-215.
45. Vanderlocht J., et al. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls. J. Neuroimmunol. 2006, 177:189-200.
46. Mahic M., et al. Human naturally occurring and adaptive regulatory T cells secrete high levels of leukaemia inhibitory factor upon activation. Scand. J. Immunol. 2008, 68:391-396.
47. Linker R.A., et al. Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. J. Immunol. 2008, 180:2204-2213.
48. Venken K., et al. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 2010, 16:58-68.
49. Gao W., et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 2009, 8:1444-1450.
50. Zhao X., et al. Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25-CD45RA+ naive T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro. Cancer Sci. 2009, 100:2143-2151.
51. Henderson A.P., et al. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 2009, 66:739-753.
52. Hendriks J.J., et al. Macrophages and neurodegeneration. Brain Res. Brain Res. Rev. 2005, 48:185-195.
53. Tofaris G.K., et al. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J. Neurosci. 2002, 22:6696-6703.
54. Duluc D., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
55. Zang D.W., Cheema S.S. Leukemia inhibitory factor promotes recovery of locomotor function following spinal cord injury in the mouse. J. Neurotrauma 2003, 20:1215-1222.
56. Asano H., et al. Astrocyte differentiation of neural precursor cells is enhanced by retinoic acid through a change in epigenetic modification. Stem Cells 2009, 27:2744-2752.
57. Weible M.W., Chan-Ling T. Phenotypic characterization of neural stem cells from human fetal spinal cord: synergistic effect of LIF and BMP4 to generate astrocytes. Glia 2007, 55:1156-1168.
58. Pitman M., et al. LIF receptor signaling modulates neural stem cell renewal. Mol. Cell Neurosci. 2004, 27:255-266.
59. Bauer S., et al. Leukemia inhibitory factor is a key signal for injury-induced neurogenesis in the adult mouse olfactory epithelium. J. Neurosci. 2003, 23:1792-1803.
60. Bauer S., Patterson P.H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J. Neurosci. 2006, 26:12089-12099.
61. Azari M.F., et al. Induction of endogenous neural precursors in mouse models of spinal cord injury and disease. Eur. J. Neurol. 2005, 12:638-648.
62. Covey M.V., Levison S.W. Leukemia inhibitory factor participates in the expansion of neural stem/progenitors after perinatal hypoxia/ischemia. Neuroscience 2007, 148:501-509.
63. Liu J., Zang D. Response of neural precursor cells in the brain of Parkinson's disease mouse model after LIF administration. Neurol. Res. 2009, 31:681-686.
64. Martino G., et al. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat. Rev. Neurol. 2010, 6:247-255.
65. Gunawardana D.H., et al. A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clin. Cancer Res. 2003, 9:2056-2065.
66. Davis I.D., et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin. Cancer Res. 2005, 11:1890-1898.
67. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 457-465.
68. Segal B.M., et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008, 7:796-804.
69. Pan W., et al. Receptor-mediated transport of LIF across blood-spinal cord barrier is upregulated after spinal cord injury. J. Neuroimmunol. 2006, 174:119-125.
70. Alvarez, J.I. et al. Disruption of central nervous system barriers in multiple sclerosis. Biochim. Biophys. Acta. (in press).
71. Pan W., et al. Neuroinflammation facilitates LIF entry into brain: role of TNF. Am. J. Physiol. Cell Physiol. 2008, 294:C1436-C1442.
72. Hughes R.A., O'Leary P.D. Exploiting neurotrophic factors for the treatment of neurodegenerative conditions: an Australian perspective. Drug Dev. Res. 1999, 46:268-276.
73. Slaets H., et al. CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis. Mol. Ther. 2010, 18:684-691.
74. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
75. Levesque I.R., et al. Quantitative magnetization transfer and myelin water imaging of the evolution of acute multiple sclerosis lesions. Magn. Reson. Med. 2010, 63:633-640.
76. Talman L.S., et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann. Neurol. 2010, 67:749-760.
77. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
78. Schwartz M., et al. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 2009, 158:1133-1142.
79. Cafferty W.B., et al. Leukemia inhibitory factor determines the growth status of injured adult sensory neurons. J. Neurosci. 2001, 21:7161-7170.
80. Shoemaker S.E., et al. A conditioning lesion enhances sympathetic neurite outgrowth. Exp. Neurol. 2005, 194:432-443.
81. Hyatt S.H., et al. The conditioning lesion effect on sympathetic neurite outgrowth is dependent on gp130 cytokines. Exp. Neurol. 2010, 223:516-522.
82. Chollangi S., et al. Preconditioning-induced protection from oxidative injury is mediated by leukemia inhibitory factor receptor (LIFR) and its ligands in the retina. Neurobiol. Dis. 2009, 34:535-544.